Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company focused on chronic low back pain, has published a shareholder letter from CEO Brent Ness detailing the company's strategic progress and key catalysts for 2026. The letter emphasizes Aclarion's pursuit of reimbursement coverage from one or more regional insurance providers in the United States, which the company views as a critical step toward broader payer adoption. Additionally, an initial readout from the ongoing CLARITY clinical trial is expected in the fourth quarter of 2026.
The company's website hosts the full CEO Shareholder Letter, which also highlights expanding commercial engagement with physicians and imaging centers. According to Ness, the company's focus remains disciplined execution against key catalysts that can expand adoption of its Nociscan platform. Nociscan is a SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine using magnetic resonance spectroscopy (MRS) data and proprietary augmented intelligence algorithms.
Aclarion reports a strong balance sheet with cash runway extending into 2028, providing financial stability to support continued operations and strategic initiatives. The company has been building clinical evidence and advancing reimbursement initiatives in both the United Kingdom and the United States. The CLARITY trial, which is enrolling patients, is expected to provide early interim results later in 2026, which could further validate Nociscan's clinical utility.
“With increasing physician engagement, growing clinical evidence, and continued progress with payers, we believe Aclarion is well positioned to advance our mission of building a scalable technology platform for chronic low back pain while creating long-term value for patients and shareholders,” Ness stated in the letter. The company's latest news and updates are available in its newsroom.
For more information on Nociscan and to find a center, Aclarion directs stakeholders to its website. The company's forward-looking statements and risk factors are detailed in its filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2025.
